Device Trial Radar · NCT02691962
Xen Matrix™ AB Surgical Graft in Ventral or Incisional Midline Hernias
Last checked: Nov 20, 2026Latest source record: Oct 21, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
75
Actual
Start
May 2016
Primary completion
May 2020
Study completion May 2020
Sponsor
- Lead sponsor
- C. R. BardPublic (BDX)
- Sponsor type
- Industry
- First posted
- Feb 25, 2016
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to prospectively explore the use of XenMatrix™ AB Surgical Graft for ventral or incisional midline hernia repair in patients across all wound classes ("All Comers") through 24 months post repair.
Conditions
- Incisional Hernia
Interventions
Xen Matrix ABDevice
Xen Matrix™ AB Surgical Graft is an acellular, sterile, non-pyrogenic porcine dermal matrix packed dry for use in the reconstruction of soft tissue deficiencies. The device surfaces are coated with the antibacterial agents Rifampin and Minocycline in a bioresorbable L-Tyrosine succinate polymer carrier.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Wound Occurrences Up to 45 Days Post ImplantationTime frame: Up to 45 days post implantation
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Keck Hospital of USC
Los Angeles, California
California Pacific Medical Center - Sutter Health
San Francisco, California
Emory University
Atlanta, Georgia
8 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.